{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:51:58Z","timestamp":1793811118027,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91116011"],"award-info":[{"award-number":["91116011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11941\/2018-2 and 15812\/2024-1"],"award-info":[{"award-number":["11941\/2018-2 and 15812\/2024-1"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["OCENW.XS21.3.066"],"award-info":[{"award-number":["OCENW.XS21.3.066"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010890","name":"CSC | Chinese Government Scholarship","doi-asserted-by":"publisher","award":["201706140153"],"award-info":[{"award-number":["201706140153"]}],"id":[{"id":"10.13039\/501100010890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The E2F\u2013RB pathway controls the G1\/S checkpoint, and tumors often bypass it through\n                    <jats:italic>RB1<\/jats:italic>\n                    or\n                    <jats:italic>CDKN2A<\/jats:italic>\n                    loss. Unlike these lesions,\n                    <jats:italic>E2F3<\/jats:italic>\n                    amplification drives persistent excessive E2F-dependent transcription through S and G2 phases. This oncogene is frequently amplified in for example bladder cancer, but its impact on the cancer cell cycle remains unclear. Using isogenic bladder cancer models and patient data, we show that\n                    <jats:italic>E2F3<\/jats:italic>\n                    amplification hyperactivates a mitotic gene expression program, including cyclin B1. This predisposes cells to unscheduled mitosis when the G2\/M checkpoint is inhibited using the PKMYT1 inhibitor lunresertib, alone or in combination with low dosages of the WEE1 inhibitor zederosertib.\n                    <jats:italic>E2F3<\/jats:italic>\n                    -amplified cells acquired resistance to lunresertib by permanently reducing cyclin B1 expression, thereby preventing premature mitotic entry. Importantly, this resistance was reversed by co-treatment with a low dose of WEE1 inhibitor. These findings identify PKMYT1-dependent CDK1 inhibition as a critical safeguard against premature mitosis in\n                    <jats:italic>E2F3<\/jats:italic>\n                    -amplified bladder cancer. Thus, we uncover an opportunity for precision medicine strategies aimed at G2\/M checkpoint inhibition to promote catastrophic mitosis in bladder cancer patients with\n                    <jats:italic>E2F3<\/jats:italic>\n                    amplification and excessive cyclin B1 expression.\n                  <\/jats:p>","DOI":"10.1038\/s41417-026-01084-x","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:08:40Z","timestamp":1790104120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["E2F3 amplification primes bladder cancer cells for premature mitosis"],"prefix":"10.1038","author":[{"given":"Kathryn A.","family":"Wierenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7046-2792","authenticated-orcid":false,"given":"Isabel S.","family":"Nieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6777-4075","authenticated-orcid":false,"given":"Pepijn R. J.","family":"Rakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Pateli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Wubbolts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4732-9447","authenticated-orcid":false,"given":"Frank M.","family":"Riemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia C.","family":"van Essen-Dorresteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsbeth A.","family":"van Liere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-3638","authenticated-orcid":false,"given":"Bart","family":"Westendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrm3629","volume":"14","author":"C Bertoli","year":"2013","unstructured":"Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14:518\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1084_CR2","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1038\/sj.onc.1207749","volume":"23","author":"M Oeggerli","year":"2004","unstructured":"Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene. 2004;23:5616\u201323.","journal-title":"Oncogene"},{"key":"1084_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u2013556.e25.","journal-title":"Cell"},{"key":"1084_CR4","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.2147\/OTT.S174103","volume":"11","author":"Z Feng","year":"2018","unstructured":"Feng Z, Peng C, Li D, Zhang D, Li X, Cui F, et al. E2F3 promotes cancer growth and is overexpressed through copy number variation in human melanoma. Onco Targets Ther. 2018;11:5303\u201313.","journal-title":"Onco Targets Ther"},{"key":"1084_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.lungcan.2006.07.005","volume":"54","author":"CS Cooper","year":"2006","unstructured":"Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A, et al. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer. 2006;54:155\u201362.","journal-title":"Lung Cancer"},{"key":"1084_CR6","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1038\/sj.onc.1209946","volume":"25","author":"M Oeggerli","year":"2006","unstructured":"Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, Mirlacher M, et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene. 2006;25:6538\u201343.","journal-title":"Oncogene"},{"key":"1084_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/sj.onc.1207274","volume":"23","author":"A Feber","year":"2004","unstructured":"Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene. 2004;23:1627\u201330.","journal-title":"Oncogene"},{"key":"1084_CR8","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1038\/sj.onc.1207800","volume":"23","author":"CS Foster","year":"2004","unstructured":"Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene. 2004;23:5871\u20139.","journal-title":"Oncogene"},{"key":"1084_CR9","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.18632\/oncotarget.1485","volume":"4","author":"H Shen","year":"2013","unstructured":"Shen H, Morrison CD, Zhang J, Underwood W 3rd, Yang N, Frangou C, et al. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 2013;4:2124\u201334.","journal-title":"Oncotarget"},{"key":"1084_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.arcmed.2012.08.009","volume":"43","author":"K Vimala","year":"2012","unstructured":"Vimala K, Sundarraj S, Sujitha MV, Kannan S. Curtailing overexpression of E2F3 in breast cancer using siRNA (E2F3)-based gene silencing. Arch Med Res. 2012;43:415\u201322.","journal-title":"Arch Med Res"},{"key":"1084_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108449","volume":"33","author":"HA Segeren","year":"2020","unstructured":"Segeren HA, van Rijnberk LM, Moreno E, Riemers FM, van Liere EA, Yuan R, et al. Excessive E2F transcription in single cancer cells precludes transient cell-cycle exit after DNA damage. Cell Rep. 2020;33:108449.","journal-title":"Cell Rep"},{"key":"1084_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17146-z","volume":"11","author":"BR Pennycook","year":"2020","unstructured":"Pennycook BR, Vesela E, Peripolli S, Singh T, Barr AR, Bertoli C, et al. E2F-dependent transcription determines replication capacity and S phase length. Nat Commun. 2020;11:3503.","journal-title":"Nat Commun"},{"key":"1084_CR13","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/onc.2010.99","volume":"29","author":"L Wiebusch","year":"2010","unstructured":"Wiebusch L, Hagemeier C. p53- and p21-dependent premature APC\/C-Cdh1 activation in G2 is part of the long-term response to genotoxic stress. Oncogene. 2010;29:3477\u201389.","journal-title":"Oncogene"},{"key":"1084_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/146282","volume":"2015","author":"MM Mc Gee","year":"2015","unstructured":"Mc Gee MM. Targeting the mitotic catastrophe signaling pathway in cancer. Mediat Inflamm. 2015;2015:146282.","journal-title":"Mediat Inflamm"},{"key":"1084_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nmeth.4045","volume":"13","author":"BT Bajar","year":"2016","unstructured":"Bajar BT, Lam AJ, Badiee RK, Oh YH, Chu J, Zhou XX, et al. Fluorescent indicators for simultaneous reporting of all four cell cycle phases. Nat Methods. 2016;13:993\u20136.","journal-title":"Nat Methods"},{"key":"1084_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279\u201384.","journal-title":"Nature"},{"key":"1084_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41388-021-02162-0","volume":"41","author":"S Guerrero Llobet","year":"2022","unstructured":"Guerrero Llobet S, Bhattacharya A, Everts M, Kok K, van der Vegt B, Fehrmann RSN, et al. An mRNA expression-based signature for oncogene-induced replication-stress. Oncogene. 2022;41:1216\u201324.","journal-title":"Oncogene"},{"key":"1084_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","volume":"604","author":"D Gallo","year":"2022","unstructured":"Gallo D, Young JTF, Fourtounis J, Martino G, Alvarez-Quilon A, Bernier C, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022;604:749\u201356.","journal-title":"Nature"},{"key":"1084_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/1535-7163.MCT-11-0024","volume":"10","author":"J Millour","year":"2011","unstructured":"Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther. 2011;10:1046\u201358.","journal-title":"Mol Cancer Ther"},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.molcel.2007.02.003","volume":"25","author":"S Larochelle","year":"2007","unstructured":"Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, et al. Requirements for Cdk7 in the assembly of Cdk1\/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell. 2007;25:839\u201350.","journal-title":"Mol Cell"},{"key":"1084_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcad029","volume":"5","author":"J Benada","year":"2023","unstructured":"Benada J, Bulanova D, Azzoni V, Petrosius V, Ghazanfar S, Wennerberg K, et al. Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma. NAR Cancer. 2023;5:zcad029.","journal-title":"NAR Cancer"},{"key":"1084_CR22","doi-asserted-by":"crossref","unstructured":"Piggott L, Gomes DBR, Sanz PM, Serra V. The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer. Cancer Res. 2025;85:2914.","DOI":"10.1158\/1538-7445.AM2025-2914"},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"Tps5634","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5634","volume":"43","author":"MM Rubinstein","year":"2025","unstructured":"Rubinstein MM, Sharma MR, Papadopoulos KP, Barretina-Ginesta MP, Garc\u00eda-Duran C, Ponz-Sarvise M, et al. Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study. J Clin Oncol. 2025;43:Tps5634.","journal-title":"J Clin Oncol"},{"key":"1084_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","volume":"145","author":"AC Bester","year":"2011","unstructured":"Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435\u201346.","journal-title":"Cell"},{"key":"1084_CR25","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1038\/onc.2012.387","volume":"32","author":"RM Jones","year":"2013","unstructured":"Jones RM, Mortusewicz O, Afzal I, Lorvellec M, Garcia P, Helleday T, et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene. 2013;32:3744\u201353.","journal-title":"Oncogene"},{"key":"1084_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.cell.2022.12.036","volume":"186","author":"J Zeng","year":"2023","unstructured":"Zeng J, Hills SA, Ozono E, Diffley JFX. Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication. Cell. 2023;186:528\u2013542.e14.","journal-title":"Cell"},{"key":"1084_CR27","doi-asserted-by":"publisher","first-page":"17997","DOI":"10.1021\/acs.jmedchem.4c01619","volume":"67","author":"M Yang","year":"2024","unstructured":"Yang M, Xiang H, Luo G. Targeting protein kinase, membrane-associated tyrosine\/threonine 1 (PKMYT1) for precision cancer therapy: from discovery to clinical trial. J Med Chem. 2024;67:17997\u20138016.","journal-title":"J Med Chem"},{"key":"1084_CR28","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-23-0564","volume":"23","author":"A Chen","year":"2024","unstructured":"Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, et al. PKMYT1 is a marker of treatment response and a therapeutic target for CDK4\/6 inhibitor-resistance in ER+ breast cancer. Mol Cancer Ther. 2024;23:1494\u2013510.","journal-title":"Mol Cancer Ther"},{"key":"1084_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1083\/jcb.141.4.875","volume":"141","author":"P Jin","year":"1998","unstructured":"Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol. 1998;141:875\u201385.","journal-title":"J Cell Biol"},{"key":"1084_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1073\/pnas.94.2.502","volume":"94","author":"J Li","year":"1997","unstructured":"Li J, Meyer AN, Donoghue DJ. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc Natl Acad Sci USA. 1997;94:502\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1084_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62061-w","volume":"16","author":"K Kim","year":"2025","unstructured":"Kim K, Armand J, Kim S, Yang HW. E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells. Nat Commun. 2025;16:6677.","journal-title":"Nat Commun"},{"key":"1084_CR32","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1038\/onc.2012.504","volume":"32","author":"JP Chow","year":"2013","unstructured":"Chow JP, Poon RY. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene. 2013;32:4778\u201388.","journal-title":"Oncogene"},{"key":"1084_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41392-025-02250-7","volume":"10","author":"B Liu","year":"2025","unstructured":"Liu B, Li W, Zhang W, Feng C, Wan L, He S, et al. PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma. Signal Transduct Target Ther. 2025;10:165.","journal-title":"Signal Transduct Target Ther"},{"key":"1084_CR34","doi-asserted-by":"crossref","unstructured":"Ehrlich MI, Fox RD, Runcie KD, Stein MN, Wei AZ. Novel strategies and therapeutic advances for bladder cancer. Cancers (Basel). 2025;17:2070.","DOI":"10.3390\/cancers17132070"},{"key":"1084_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.270.5233.86","volume":"270","author":"PR Mueller","year":"1995","unstructured":"Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science. 1995;270:86\u201390.","journal-title":"Science"},{"key":"1084_CR36","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/j.1460-2075.1995.tb07210.x","volume":"14","author":"CH McGowan","year":"1995","unstructured":"McGowan CH, Russell P. Cell cycle regulation of human WEE1. EMBO J. 1995;14:2166\u201375.","journal-title":"EMBO J"},{"key":"1084_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1083\/jcb.200909144","volume":"189","author":"O Gavet","year":"2010","unstructured":"Gavet O, Pines J. Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. J Cell Biol. 2010;189:247\u201359.","journal-title":"J Cell Biol"},{"key":"1084_CR38","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/0008-5472.CAN-19-1961","volume":"79","author":"CW Lewis","year":"2019","unstructured":"Lewis CW, Bukhari AB, Xiao EJ, Choi WS, Smith JD, Homola E, et al. Upregulation of Myt1 promotes acquired resistance of cancer cells to Wee1 inhibition. Cancer Res. 2019;79:5971\u201385.","journal-title":"Cancer Res"},{"key":"1084_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00729-2","volume":"12","author":"MA Wood","year":"2020","unstructured":"Wood MA, Weeder BR, David JK, Nellore A, Thompson RF. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Med. 2020;12:33.","journal-title":"Genome Med"},{"key":"1084_CR40","doi-asserted-by":"crossref","unstructured":"Lee T, MacDonald L, Lawen T, Kamat AM. Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what\u2019s new in 2025? Expert Rev Anticancer Ther. 2025;25:1181\u201393.","DOI":"10.1080\/14737140.2025.2535657"},{"key":"1084_CR41","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/s41388-022-02291-0","volume":"41","author":"HA Segeren","year":"2022","unstructured":"Segeren HA, van Liere EA, Riemers FM, de Bruin A, Westendorp B. Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53. Oncogene. 2022;41:2719\u201333.","journal-title":"Oncogene"},{"key":"1084_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41592-022-01507-1","volume":"19","author":"D Ershov","year":"2022","unstructured":"Ershov D, Phan MS, Pylvanainen JW, Rigaud SU, Le Blanc L, Charles-Orszag A, et al. TrackMate 7: integrating state-of-the-art segmentation algorithms into tracking pipelines. Nat Methods. 2022;19:829\u201332.","journal-title":"Nat Methods"},{"key":"1084_CR43","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.devcel.2020.01.024","volume":"52","author":"B Benedict","year":"2020","unstructured":"Benedict B, van Schie JJM, Oostra AB, Balk JA, Wolthuis RMF, Riele HT, et al. WAPL-dependent repair of damaged DNA replication forks underlies oncogene-induced loss of sister chromatid cohesion. Dev Cell. 2020;52:683\u2013698.e7.","journal-title":"Dev Cell"},{"key":"1084_CR44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"1084_CR45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinforma"},{"key":"1084_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Curr Protoc. 2021;1:e90.","journal-title":"Curr Protoc"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01084-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:08:43Z","timestamp":1790104123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01084-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":46,"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01084-x","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was partly sponsored by Repare Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"No ethics approvals were required for this study as it did not involve patients or animals. All methods were performed in accordance with the relevant guidelines and regulations. GMO work on cell lines were approved by permits 15-0054_I and 20-266_II.","order":2,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Ethics"}}]}}